Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To demonstrate superior clinical efficacy as measured by progression free survival (PFS) of bevacizumab in combination with rituximab and CHOP (RA-CHOP) versus R-CHOP alone for the treatment of previously untreated patients with diffuse large B cell lymphoma (DLBCL) with at least low-intermediate risk disease according to the IPI or bulky disease regardless of IPI risk category.
Critère d'inclusion
- Previously untreated CD20-positive Diffuse Large B-Cell Lymphoma (DLBCL) patients